Questions
Ipamorelin: common questions, answered from the studies
Direct answers, cited where the claim is quantitative.
Does ipamorelin reduce belly fat?
No human trial has tested ipamorelin for belly fat. The most relevant recent data come from a 2024 ferret study, where intraperitoneal ipamorelin (1-3 mg/kg) cut cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase [5] — a study about preventing weight loss, not reducing fat. Community reports of a gradually leaner look are anecdotal and confounded by diet and training.
Is there new research on ipamorelin in 2024?
Yes. The most recent in-vivo study, from 2024, gave ipamorelin to ferrets and found that 1-3 mg/kg intraperitoneally inhibited cisplatin-induced body-weight loss by roughly 24% in the delayed phase, with no anti-emetic effect [5]. A 2024 study of unacylated ghrelin — the same receptor family — showed protection against age-related muscle loss [11]. Several 2026 reviews then synthesized the field [12][13][14].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and the first selective growth hormone secretagogue. In its founding characterization it released growth hormone potently in rat pituitary cells, anaesthetised rats, and conscious swine (swine ED50 2.3 nmol/kg vs 3.9 for GHRP-6), yet did not raise ACTH or cortisol even more than 200-fold above its growth-hormone ED50 [1]. It is not an approved drug.
What does ipamorelin do for you?
In research terms, ipamorelin activates the ghrelin receptor (GHS-R1a) on pituitary cells and triggers a discrete pulse of growth hormone, doing so without meaningfully raising cortisol or prolactin [1]. That is what the studies measured. Claims about what it does "for you" personally — fat loss, anti-aging — are not supported by controlled human trials; the one human efficacy trial, for bowel recovery, failed [3].
What is ipamorelin peptide?
The ipamorelin peptide is a five-amino-acid chain (a pentapeptide) engineered for protease resistance with a non-natural amino acid at position one and two D-form residues [1]. It is derived from GHRP-1 by removing the central Ala-Trp dipeptide, and it works as a selective agonist of the ghrelin / growth hormone secretagogue receptor. It is wholly synthetic and not an endogenous human peptide.
What are the risks of ipamorelin?
The honest risk picture is dominated by missing data. The only Phase 2 RCT (114 adults, up to 7 days IV) missed its primary endpoint, with adverse events in 87.5% of the ipamorelin arm vs 94.8% of placebo — no specific signal in that short window, but no long-term human safety database [3]. Mechanistic and class-level cautions cover cancer, glucose control, and cardiovascular safety — detailed on the effects page.
What are the downsides of ipamorelin?
The central downside is that efficacy in humans is unproven and long-term safety is uncharacterized — the one human efficacy trial failed its endpoint [3]. Commonly reported anecdotal downsides include post-injection flushing, transient appetite increase, mild water retention, and injection-site irritation, all unverified. A related-compound study also flags a class-level cardiac signal [6].
Why is ipamorelin being discontinued?
Ipamorelin's clinical development ended because its only Phase 2 trial failed: median time to first tolerated meal was 25.3 h with ipamorelin vs 32.6 h with placebo (p=0.15), missing the primary endpoint [3]. It was never an approved product to discontinue. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access.
What does CJC-1295 and ipamorelin do?
Together they stimulate growth-hormone release through two complementary receptors — CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor [1]. A 2026 narrative review found the combination improved maximal muscle tetanic tension in a glucocorticoid-induced muscle-loss model in mice, while noting the evidence is limited to animal studies [12]. No controlled human trial has tested the combination.
Does ipamorelin increase IGF-1?
Indirectly and inconsistently. Ipamorelin releases growth hormone, which drives the liver to make IGF-1, but IGF-1 was not consistently elevated in short rodent studies — a rat bone-growth study found no change in total IGF-1 despite increased bone growth [4]. In off-label human use, an observational report on combined growth hormone secretagogue therapy in hypogonadal men did find raised serum IGF-1 [16].
How does CJC-1295 ipamorelin work?
CJC-1295 ipamorelin works by hitting two separate growth-hormone-release pathways at once: CJC-1295 supplies a sustained GHRH signal through the GHRH receptor's cAMP pathway, while ipamorelin adds a selective ghrelin-receptor pulse through calcium signaling [1]. Because the doorways are distinct and complementary, the combined pulse is larger than either alone in preclinical work [12].
How much CJC-1295 ipamorelin should I take?
No controlled human trial has established a dose for the combination, so there is no research-grounded answer. The only human ipamorelin trial used a fixed research dose (0.03 mg/kg IV twice daily) for a hospital indication that failed [3]. Subcutaneous 'stack' regimens in forums have no peer-reviewed human dosing basis and are anecdotal — this site does not provide dosing guidance.
Does CJC-1295 ipamorelin work?
Mechanistically the combination produces a real growth-hormone effect, and a 2026 review reports it improved maximal muscle tetanic tension in a mouse model [12]. For human body-composition or anti-aging outcomes, there is no controlled-trial evidence, and the single human ipamorelin efficacy trial failed its endpoint [3]. The biology is supported; specific human outcome claims are not.
How to reconstitute CJC-1295 ipamorelin 5mg?
Ipamorelin is supplied as a lyophilized powder and reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and freeze-thaw, so solution is kept refrigerated. These are general research-supply handling notes, not a clinical preparation instruction or a direction for human use — this site provides no injection guidance.
How long does ipamorelin stay in your system?
In the one human pharmacokinetic study, the terminal half-life was about 2 hours, with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg [2]. The growth-hormone pulse it triggers peaks near 40 minutes after dosing [2]. Note that detection windows for anti-doping purposes can exceed the pharmacokinetic half-life, since assays target the molecule and its signatures.
Does ipamorelin make you hungry?
It can, mechanistically. Ipamorelin acts on the ghrelin receptor, and ghrelin-receptor agonists activate the brain's appetite centers and induce feeding in animal studies [10]. Community accounts describe an appetite uptick after injection, generally milder than with GHRP-6 — anecdotal and unverified. The effect is a recognized feature of the receptor class, not a guaranteed individual response.
Will I gain weight on ipamorelin?
There is no human trial answer. Ipamorelin showed growth-hormone-independent stimulation of adiposity in mice [9], and its ghrelin-receptor mechanism can raise appetite [10], so weight change is plausible but unmeasured in humans at research-use doses. The one human ipamorelin trial was a short perioperative study not designed to assess body weight [3]. Community reports vary and are confounded by diet and training.
Does ipamorelin increase appetite?
Yes, in mechanism and in animal data. As a ghrelin-receptor agonist, ipamorelin engages the same system the hunger hormone uses, and central ghrelin and growth hormone secretagogues induce feeding in rodents [10]. Reported real-world appetite increases are generally described as milder than with older peptides but remain an unwanted effect for some users — anecdotal and unverified.
What does ipamorelin peptide do?
The ipamorelin peptide selectively activates the ghrelin / growth hormone secretagogue receptor on pituitary cells, producing a discrete growth-hormone pulse without meaningfully raising cortisol or prolactin [1]. Downstream it can drive the IGF-1 axis, though inconsistently in short studies [4]. Beyond the pituitary, it has documented effects on pancreatic insulin release and gut motility in preclinical models [8].
How long does it take for ipamorelin to work?
Pharmacologically, fast: the growth-hormone pulse peaks roughly 40 minutes after a dose, and the terminal half-life is about 2 hours in humans [2]. Subjective effects that users report — such as sleep changes — are typically described as appearing over one to two weeks of use, but those timelines are anecdotal and not measured in controlled trials.
Does ipamorelin cause water retention?
Possibly, by mechanism. Growth-hormone excess is associated with sodium and water retention, so raising growth-hormone pulses could promote mild fluid retention [6]. Community reports describe transient puffiness in fingers, ankles, or face in the first weeks, generally milder than with older peptides and easing with continued use — anecdotal and unverified, with no controlled human data at research-use doses.
Where to inject CJC-1295 ipamorelin?
This site provides no injection or self-administration guidance. In the published human ipamorelin studies the route was intravenous infusion under controlled conditions [2][3]; subcutaneous administration is the dominant route in off-label community use but has no published human safety or pharmacokinetic characterization. Questions about administering any unapproved peptide belong with a qualified clinician, not a research digest.